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Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although
idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special
patient-populations such as sepsis and impaired renal function. Case Presentation. We present the case of a 67-year-old male septic
patient with amultilocular facial abscess and chronic kidney disease (GFR 36.5mL/min).Thrombin time (TT) and activated partial
thromboplastin time (aPTT) 15 hours after the last intake of 150mg dabigatran were both prolonged (>120 sec, resp., 61 sec), as
well as unbound dabigatran concentration (119.05 ng/mL). Before immediate emergency surgery dabigatran was antagonised using
idarucizumab 2 × 2.5 g. Dabigatran concentration was not detectable 10min after idarucizumab administration (<30 ng/mL). TT
and aPTT time were normalised (16.2 sec, resp., 30.2 sec). Sepsis was controlled after surgery and kidney function remained stable.
In the absence of postoperative bleeding, dabigatran was restarted 36 hours after admission. Conclusion. Idarucizumab successfully
reversed the effect of dabigatran in real-life practice in a patient with sepsis and renal impairment and allowed emergency surgery
with normal haemostasis. Efficacy and safety in real-life practice will nevertheless require prospective registries monitoring.
1. Introduction
Immediate reversal of anticoagulation is essential when
facing severe bleeding or emergency surgery. Even though
the use of direct oral anticoagulants is rapidly increasing, no
antidote for the reversal of dabigatran was available for use
in clinical practice so far [1, 2]. Haemodialysis of dabigatran
is possible but time consuming and not available in all cases
[3, 4]. In 2015, the FDA and EMA approved idarucizumab
(Praxbind©), a monoclonal antibody, for the specific inac-
tivation of dabigatran by direct binding. However, approval
was based on a single-arm prospective observational study
with laboratory measures as primary endpoint only [5].
Idarucizumab is rapidly eliminated by the kidney with a
mean plasma concentration decreased by 80% from the peak
level 4 hours after administration [5]. Elimination in patients
with severely impaired renal function is unclear. Efficacy
of idarucizumab in clinical practice with regard to clinical
endpoints is unknown, in particular in special populations
such as renal impairment or sepsis.
2. Case Presentation
The 67-year-old male patient was admitted to our emergency
department because of swelling in his right cheek since the
previous day. He had a history of atrial fibrillation, which had
been treated with dabigatran, 150mg twice daily (last dose
15-16 hours before presentation), and suffered from chronic
renal impairment due to type II diabetes mellitus and hyper-
tension. The febrile patient was haemodynamically stable on
admission.The physical examination revealed significant hot
and painful right facial swelling. The laboratory results on
admission were as follows: white blood count 17.7 Giga/L;
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Table 1: Coagulation tests.
Parameter Standard values Before idarucizumab 10 minutes after 2 × 2.5 gidarucizumab
24 hours after
idarucizumab
INR 1.56 1.23 1.10
aPTT (sec) 25.0–36.0 61 30.2 41.5
Thrombin time (sec) 11.5–19.4 >120 16.2 52.9
Fibrinogen (g/L) 1.75–3.75 7.11 7.11 7.09
Dabigatran (ng/mL) 119.05 <30.0 <30.0
Activated partial thromboplastin time (aPTT); international normalised ratio (INR).
C-reactive protein 234mg/L; creatinine 165 𝜇mol/L (GFR
36.5mL/min); and unbound dabigatran concentration as
measured with diluted thrombin time (dTT; Hyphen Hemo-
clot, Neuville-sur-Oise, France) 119.05 ng/mL. The activated
partial thromboplastin time (aPTT) and thrombin time
were prolonged (61 sec, resp., <120 sec). For a summary of
coagulation tests, see Table 1. We administered 2.2 g i.v. Co-
Amoxicillin and computed tomography was performed to
plan abscess surgery.
As the patient was becoming increasingly septic and
haemodynamically unstable despite volume substitution,
emergency surgery was indicated.
We administered a 2.5 g infusion of idarucizumab, fol-
lowed by a second infusion of 2.5 g idarucizumab after 10
minutes. No side effects were reported by the patient.
Immediately after the second dose, coagulation testing
was repeated and aPTT as well as thrombin time were
found to be normal; dabigatran concentration was below
detection limit (<30 ng/mL; see Table 1). Thirty minutes after
idarucizumab application, enoral incision of the multilocular
abscess was performed, with irrigation and insertion of
Penrose and Easy Flow drainage.There was no relevant blood
loss and no other complications. The surgical team rated the
intraoperative bleeding as being “as expected.”
The patient could be managed postoperatively on an
ordinary surgical ward with rapid clinical improvement.
Coagulation tests were repeated 24 hours after administration
of idarucizumab (Table 1). Postoperative kidney function
improved after treatment of infection (creatinine 115 𝜇mol/L,
GFR 56mL/min, day 6). As there was no postoperative
bleeding, dabigatran was restarted 36 hours after surgery and
administration of idarucizumab. The patient was discharged
from hospital without any complications.
3. Discussion
We report the successful administration of idarucizumab to
a septic patient with chronic kidney disease, in order to
facilitate emergency surgery for facial abscess.
Although our patient presented about 15-16 hours after
the last 150mg dose of dabigatran, coagulation tests were still
markedly prolonged and a relevant dabigatran concentration
was present. Given the patient’s rapid clinical deterioration
and his impaired renal function, we decided to administer
the antidote, rather than waiting for the dabigatran to be
cleared. As only 13 patients in the RE-VERSE AD study
(33%) had creatinine clearance <50mL/min, experience with
application of idarucizumab and restarting of dabigatran in
patients with impaired renal function is limited [5].
The RE-VERSE AD trail included two patients with
abscesses only, in the suprapubic and scrotal locations [5].
However, bleeding in abscess surgery can be critical, partic-
ularly in oral surgery where haemorrhages may compromise
the airway and lead to aspiration that requires invasive airway
management. In our patient, reversal of anticoagulation led
to immediate normalisation of all coagulation tests. Normal
intraoperative haemostasis, as reported by the surgical team
in our case, is consistent with the 92% of patients in the RE-
VERSE AD trail [5].
Twenty-four hours after surgery and administration of
idarucizumab, we found that aPTT and thrombin time
were mildly prolonged again. Most probably, these changes
are caused by redistribution of unbound dabigatran not
detected by the diluted thrombin time. Even in patients with
severe renal impairment idarucizumab is most likely to be
cleared at 24 h hours and therefore cannot bind redistributed
dabigatran anymore. It has been previously reported that even
very low doses of 25 ng/mL dabigatran (below the detection
limit of our test, <30 ng/mL) may lead to immeasurably high
thrombin times [6].This prolongation in the coagulation tests
did not lead to any clinical bleeding in our patient but may
cause confusion. It is important to point out that the aPTT is
likely to be prolonged in the presence of dabigatran, but the
degree of prolongation does not correlate well with the level
of anticoagulant activity.
In-hospital acute kidney injury is common, especially
in patients with sepsis (2–18% of all hospital inpatients)
and needs close monitoring of renal function to determine
whether and at which dosage therapy with dabigatran can be
continued [7, 8]. In our patient, the kidney function improved
after treatment of infection and he could be discharged with
dabigatran into the care of his general practitioner for close
monitoring.
4. Conclusion
Idarucizumab reversed the effect of dabigatran treatment
successfully in real-life practice in a patient with sepsis
and renal impairment and allowed emergency surgery with
normal haemostasis. As there is limited experience with
idarucizumab efficacy and safety in real-life practice shall be
monitored in prospective registries.
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